Sell Dollar Tree Heading Into Q3 Earnings

Group 1 - Brendan completed a Ph.D. at Stanford University in organic synthesis in 2009 [1] - He worked for Merck from 2009 to 2013 and has experience in biotech startups such as Theravance and Aspira [1] - Brendan is the first employee and co-founder of 1200 Pharma, which spun out of Caltech and received significant investment in the 8 figures [1] Group 2 - The author is considering options trades related to DLTR earnings, indicating a speculative nature of the trade [3] - The outcome of the options trades will be clear by December 6th, highlighting a timeline for potential investment decisions [3]